Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment 

Gut Germs Appear to Play Role in Multiple Sclerosis 
October 12, 2017
Rheumatoid Arthritis Medications: Common Mistakes
October 12, 2017
Show all

Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment 

Hepatitis C medications need to reach additional infected populations.

Valerie Green is still waiting to be cured.

The Delaware resident was diagnosed with hepatitis C more than two years ago, but she doesn’t qualify yet for the Medicaid program’s criteria for treatment with a new class of highly effective but pricey drugs. The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and correctional facilities to expand treatment.

The drug, Mavyret, is the first to be approved by the Food and Drug Administration that can cure all six genetic types of hepatitis C in about two months in patients who haven’t previously been treated. Other approved drugs generally require 12 weeks to treat the disease and often aren’t effective for all types of hepatitis C.

Read full article: Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment | Kaiser Health News

Read Full Article: Hepatitis C Drug’s Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment | Kaiser Health News

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.